Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jul 12;7(7):CD012638.
doi: 10.1002/14651858.CD012638.pub2.

Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults

Sheena Derry  1 , Philip J Wiffen, R Andrew Moore, Ewan D McNicol, Rae F Bell, Daniel B Carr, Mairead McIntyre, Bee Wee
Affiliations
Meta-Analysis

Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults

Sheena Derry et al. Cochrane Database Syst Rev. .

Abstract

Background: Pain is a common symptom with cancer, and 30% to 50% of all people with cancer will experience moderate to severe pain that can have a major negative impact on their quality of life. Non-opioid drugs are commonly used to treat cancer pain, and are recommended for this purpose in the World Health Organization (WHO) cancer pain treatment ladder, either alone or in combination with opioids.A previous Cochrane review that examined the evidence for nonsteroidal anti-inflammatory drugs (NSAIDs) or paracetamol, alone or combined with opioids, for cancer pain was withdrawn in 2015 because it was out of date; the date of the last search was 2005. This review, and another on paracetamol, updates the evidence.

Objectives: To assess the efficacy of oral NSAIDs for cancer pain in adults, and the adverse events reported during their use in clinical trials.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase from inception to April 2017, together with reference lists of retrieved papers and reviews, and two online study registries.

Selection criteria: We included randomised, double-blind, single-blind, or open-label studies of five days' duration or longer, comparing any oral NSAID alone with placebo or another NSAID, or a combination of NSAID plus opioid with the same dose of the opioid alone, for cancer pain of any pain intensity. The minimum study size was 25 participants per treatment arm at the initial randomisation.

Data collection and analysis: Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality and potential bias. We did not carry out any pooled analyses. We assessed the quality of the evidence using GRADE and created a 'Summary of findings' table.

Main results: Eleven studies satisfied inclusion criteria, lasting one week or longer; 949 participants with mostly moderate or severe pain were randomised initially, but fewer completed treatment or had results of treatment. Eight studies were double-blind, two single-blind, and one open-label. None had a placebo only control; eight compared different NSAIDs, three an NSAID with opioid or opioid combination, and one both. None compared an NSAID plus opioid with the same dose of opioid alone. Most studies were at high risk of bias for blinding, incomplete outcome data, or small size; none was unequivocally at low risk of bias.It was not possible to compare NSAIDs as a group with another treatment, or one NSAID with another NSAID. Results for all NSAIDs are reported as a randomised cohort. We judged results for all outcomes as very low-quality evidence.None of the studies reported our primary outcomes of participants with pain reduction of at least 50%, and at least 30%, from baseline; participants with Patient Global Impression of Change (PGIC) of much improved or very much improved (or equivalent wording). With NSAID, initially moderate or severe pain was reduced to no worse than mild pain after one or two weeks in four studies (415 participants in total), with a range of estimates between 26% and 51% in individual studies.Adverse event and withdrawal reporting was inconsistent. Two serious adverse events were reported with NSAIDs, and 22 deaths, but these were not clearly related to any pain treatment. Common adverse events were thirst/dry mouth (15%), loss of appetite (14%), somnolence (11%), and dyspepsia (11%). Withdrawals were common, mostly because of lack of efficacy (24%) or adverse events (5%).

Authors' conclusions: There is no high-quality evidence to support or refute the use of NSAIDs alone or in combination with opioids for the three steps of the three-step WHO cancer pain ladder. There is very low-quality evidence that some people with moderate or severe cancer pain can obtain substantial levels of benefit within one or two weeks.

PubMed Disclaimer

Conflict of interest statement

PW: none known.

SD: none known.

RAM has received grant support from Grünenthal relating to individual patient level analyses of trial data regarding tapentadol in osteoarthritis and back pain (2015). He has received honoraria for attending boards with Menarini concerning methods of analgesic trial design (2014), with Novartis (2014) about the design of network meta‐analyses, and RB on understanding pharmacokinetics of drug uptake (2015). He has received honoraria from Omega Pharma (2016) and Futura Pharma (2016) for providing advice on trial and data analysis methods.

EDM: none known.

RFB: none known; RFB is a specialised pain physician and has managed patients with cancer pain.

DBC: none known; DBC is a specialised pain physician and has managed patients with cancer pain.

MM: none known.

BW: none known. BW is a specialist Palliative Medicine Consultant physician and manages patients with advanced life threatening illnesses, including cancer.

This review was identified in a 2019 audit as not meeting the current definition of the Cochrane Commercial Sponsorship policy. At the time of its publication it was compliant with the interpretation of the existing policy. As with all reviews, new and updated, at update this review will be revised according to 2020 policy update.

Figures

1
1
Study flow diagram.
2
2
'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Carlson 1990 {published data only}
    1. Carlson RW, Borrison RA, Sher HB, Eisenberg PD, Mowry PA, Wolin EM. A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Pharmacotherapy 1990;10(3):211‐6. [DOI: 10.1002/j.1875-9114.1990.tb02577.x] - DOI - PubMed
Gallucci 1992 {published data only}
    1. Cantarelli A, Giannunzio D, Ligorio L, Mapelli A, Veca G, Gallucci M, et al. Comparison of nimesulide and naproxen sodium in the control of cancer pain [Confronto fra nimesulide e naproxene sodico nel controllo del dolore da cancro]. Minerva Anestesiologica 1991;57(10):1103‐4. [PUBMED: 1961495] - PubMed
    1. Gallucci M, Toscani F, Mapelli A, Cantarelli A, Veca G, Scaricabarozzi I. Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Arzneimittelforschung 1992;42(8):1028‐30. [PUBMED: 1418076] - PubMed
    1. Toscani F, Gallucci M, Scaricabarozzi I. Nimesulide in the treatment of advanced cancer pain. Double‐blind comparison with naproxen. Drugs 1993;46 (Suppl 1):156‐8. [PUBMED: 7506159] - PubMed
Minotti 1989 {published data only}
    1. Minotti V, Patoia L, Roila F, Basurto C, Tonato M, Pasqualucci V, et al. Double‐blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain 1989;36(2):177‐83. [DOI: 10.1016/0304-3959(89)90021-3] - DOI - PubMed
Mohammadinejad 2015 {published data only}
    1. Mohammadinejad P, Arya P, Esfandbod M, Kaviani A, Najafi M, Kashani L, et al. Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double‐blind, placebo‐controlled, randomized trial. Annals of Pharmacotherapy 2015;49(9):953‐61. [DOI: 10.1177/1060028015592215; ICTRP: IRCT201405271556N58] - DOI - PubMed
Pannuti 1999 {published data only}
    1. Pannuti F, Robustelli della Cuna G, Ventaffrida V, Strocchi E, Camaggi CM. A double‐blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Tumori 1999;85(2):96‐100. [PUBMED: 10363074] - PubMed
Rodriguez 1994 {published data only}
    1. Rodríguez M, Barutell C, Rull M, Gálvez R, Pallarés J, Vidal F, et al. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. European Journal of Cancer 1994;30A(5):584‐7. [PUBMED: 8080670] - PubMed
Rodriguez 2003 {published data only}
    1. Rodríguez MJ, Contreras D, Gálvez R, Castro A, Camba MA, Busquets C, et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain 2003;104(1‐2):103‐10. [DOI: 10.1016/S0304-3959(02)00470-0] - DOI - PubMed
Toscani 1994 {published data only}
    1. Toscani F, Piva L, Corli O, Gallucci M, Speranza R, Tamburini M, et al. Ketorolac versus diclofenac sodium in cancer pain. Arzneimittelforschung 1994;44(4):550‐4. [PUBMED: 8011010] - PubMed
Turnbull 1986 {published data only}
    1. Turnbull R, Hills LJ. Naproxen versus aspirin as analgesics in advanced malignant disease. Journal of Palliative Care 1986;1(2):25‐8. [PUBMED: 3450812] - PubMed
Ventafrida 1990a {published data only}
    1. Ventafridda V, Toscani F, Tamburini M, Corli O, Gallucci M, Gottlieb A, et al. Sodium naproxen versus sodium diclofenac in cancer pain control. Arzneimittelforschung 1990;40(10):1132‐4. [PUBMED: 2291751] - PubMed
Yalçin 1998 {published data only}
    1. Yalçin S, Güllü IH, Tekuzman G, Savaş C, Firat D. A comparison of two nonsteroidal antiinflammatory drugs (diflunisal versus dipyrone) in the treatment of moderate to severe cancer pain: a randomized crossover study. American Journal of Clinical Oncology 1998;21(2):185‐8. [PUBMED: 9537209] - PubMed

References to studies excluded from this review

Bjorkman 1993 {published data only}
    1. Björkman R, Ullman A, Hedner J. Morphine‐sparing effect of diclofenac in cancer pain. European Journal of Clinical Pharmacology 1993;44(1):1‐5. [DOI: 10.1007/BF00315271] - DOI - PubMed
Bosek 1994 {published data only}
    1. Bosek V, Miguel R. Comparison of morphine and ketorolac for intravenous patient‐controlled analgesia in postoperative cancer patients. Clinical Journal of Pain 1994;10(4):314‐8. [PUBMED: 7858362] - PubMed
Chary 1994 {published data only}
    1. Chary S, Goughnour BR, Moulin DE, Thorpe WR, Harsanyi Z, Darke AC. The dose‐response relationship of controlled‐release codeine (Codeine Contin) in chronic cancer pain. Journal of Pain and Symptom Management 1994;9(6):363‐71. [DOI: 10.1016/0885-3924(94)90173-2] - DOI - PubMed
Chen 2003 {published data only}
    1. Chen Y, Zhu W, Liang H, Wu G. The analgesic effect of ibuprofen‐codeine sustained release tablets on postoperative and cancer pain. Chinese Journal of Clinical Rehabilitation 2003;7(8):1290‐1. [CENTRAL: CN‐01305289]
Corli 1993 {published data only}
    1. Corli O, Cozzolino A, Scaricabarozzi I. Nimesulide and diclofenac in the control of cancer‐related pain. Comparison between oral and rectal administration. Drugs 1993;46 (Suppl 1):152‐5. [PUBMED: 7506158] - PubMed
Dellemijn 1994 {published data only}
    1. Dellemijn PLI, Verbiest HBC, Vliet JJ, Roos PJ, Vecht CJ. Medical therapy of malignant nerve pain. A randomized double‐blind explanatory trial with naproxen versus slow‐release morphine. European Journal of Cancer 1994;30A(9):1244‐50. [PUBMED: 7999406] - PubMed
    1. Dellemijn PLI, Verbiest HBC, Vliet JJ, Putten WLJ, Vecht CJ. Nociceptive nerve pain in cancer: a double‐blind study with naproxen versus slow‐release morphine. Clinical Neurology and Neurosurgery 1993;95:331. [CENTRAL: CN‐00364074]
Dutre Souza 2007 {published data only}
    1. Duarte Souza JF, Lajolo PP, Pinczowski H, Giglio A. Adjunct dipyrone in association with oral morphine for cancer‐related pain: the sooner the better. Supportive Care in Cancer 2007;15(11):1319‐23. [DOI: 10.1007/s00520-007-0327-7] - DOI - PubMed
Estapé 1990 {published data only}
    1. Estapé J, Viñolas N, González B, Inglés F, Bofill T, Guzmán MC, et al. Ketorolac, a new non‐opioid analgesic: a double‐blind trial versus pentazocine in cancer pain. Journal of International Medical Research 1990;18(4):298‐304. [DOI: 10.1177/030006059001800406] - DOI - PubMed
Ferrer‐Brechner 1984 {published data only}
    1. Ferrer‐Brechner T, Ganz P. Combination therapy with ibuprofen and methadone for chronic cancer pain. American Journal of Medicine 1984;77(1A):78‐83. [DOI: 10.1016/S0002-9343(84)80023-6] - DOI - PubMed
Frankendal 1973 {published data only}
    1. Frankendal B. Clinical testing of a new analgesic combination on cancer patients in chronic pain [Klinisk provning av ny analgetikakombination pa cancerpatienter med kroniska smartor]. Lakartidningen 1973;70(10):949‐51. [PUBMED: 4572816] - PubMed
Johnson 1994 {published data only}
    1. Johnson JR, Miller AJ. The efficacy of choline magnesium trisalicylate (CMT) in the management of metastatic bone pain: a pilot study. Palliative Medicine 1994;8(2):129‐35. [DOI: 10.1177/026921639400800206] - DOI - PubMed
Lauretti 1999 {published data only}
    1. Lauretti GR, Lima IC, Reis MP, Prado WA, Pereira NL. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 1999;90(6):1528‐33. [PUBMED: 10360847] - PubMed
Levick 1988 {published data only}
    1. Levick S, Jacobs C, Loukas DF, Gordon DH, Meyskens FL, Uhm K. Naproxen sodium in treatment of bone pain due to metastatic cancer. Pain 1988;35(3):253‐8. [DOI: 10.1016/0304-3959(88)90134-0] - DOI - PubMed
Lomen 1986 {published data only}
    1. Lomen PL, Samal BA, Lamborn KR, Sattler LP, Crampton SL. Flurbiprofen for the treatment of bone pain in patients with metastatic breast cancer. American Journal of Medicine 1986;80(3A):83‐7. [DOI: 10.1016/0002-9343(86)90118-X] - DOI - PubMed
Martino 1976 {published data only}
    1. Martino G, Ventafridda V, Parini J, Emanueli A. A controlled study on the analgesic activity of indoprofen inpatients with cancer pain. In: Bonica JJ, Albe‐Fessard D editor(s). Pharmacological Agents in Chronic Pain, Advances in Pain Research and Therapy. Vol. 1, New York: Raven Press, 1976:573‐8.
Mercadante 2002 {published data only}
    1. Mercadante S, Fulfaro F, Casuccio A. A randomised controlled study on the use of anti‐inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose‐escalation and a pharmacoeconomic analysis. European Journal of Cancer 2002;38(10):1358‐63. [DOI: 10.1016/S0959-8049(02)00102-8] - DOI - PubMed
Minotti 1998a {published data only}
    1. Minotti V, Betti M, Ciccarese G, Fumi G, Tonato M, Favero A. A double‐blind study comparing two single‐dose regimens of ketorolac with diclofenac in pain due to cancer. Pharmacotherapy 1998;18(3):504–8. [PUBMED: 9620101] - PubMed
Minotti 1998b {published data only}
    1. Minotti V, Angelis V, Righetti E, Celani MG, Rossetti R, Lupatelli M, et al. Double‐blind evaluation of short‐term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain. Pain 1998;74(2‐3):133‐7. [PUBMED: 9520227] - PubMed
Moertel 1971 {published data only}
    1. Moertel CG, Ahmann DL, Taylor WF, Schwartau N. Aspirin and pancreatic cancer pain. Gastroenterology 1871;60(4):552‐3. [PUBMED: 5573227] - PubMed
Moertel 1974 {published data only}
    1. Moertel CG, Ahmann DL, Taylor WF, Schwartau N. Relief of pain by oral medications. A controlled evaluation of analgesic combinations. JAMA 1974;229(1):55‐9. [DOI: 10.1001/jama.1974.03230390031020] - DOI - PubMed
Sacchetti 1984 {published data only}
    1. Sacchetti G, Camera P, Rossi AP, Martoni A, Bruni G, Pannuti F. Injectable ketoprofen vs. acetylsalicylic acid for the relief of severe cancer pain: a double‐blind, crossover trial. Drug Intelligence and Clinical Pharmacy 1984;18(5):403‐6. [PUBMED: 6373214] - PubMed
Saxena 1994 {published data only}
    1. Saxena A, Andley M, Gnanasekaran N. Comparison of piroxicam and acetylsalicylic acid for pain in head and neck cancers: a double‐blind study. Palliative Medicine 1994;8(3):223‐9. [DOI: 10.1177/026921639400800306] - DOI - PubMed
Shen 2003 {published data only}
    1. Shen W, Chen Q. The efficacy and tolerability of lornoxicam in treatment of pain in metastatic carcinoma of bone. Chinese Journal of New Drugs 2003;12(7):561‐3. [CENTRAL: CN‐00495555]
Stambaugh 1988a {published data only}
    1. Stambaugh J, Drew J. A double‐blind parallel evaluation of the efficacy and safety of a single dose of ketoprofen in cancer pain. Journal of Clinical Pharmacology 1988;28(12 (Suppl)):S34‐9. [DOI: 10.1002/j.1552-4604.1988.tb05975.x] - DOI - PubMed
Stambaugh 1988b {published data only}
    1. Stambaugh JE Jr, Drew J. The combination of ibuprofen and oxycodone/acetaminophen in the management of chronic cancer pain. Clinical Pharmacology and Therapeutics 1988;44(6):665‐9. [DOI: 10.1038/clpt.1988.209] - DOI - PubMed
Staquet 1989 {published data only}
    1. Staquet MJ. A double‐blind study with placebo control of intramuscular ketorolac tromethamine in the treatment of cancer pain. Journal of Clinical Pharmacology 1989;29(11):1031‐6. [DOI: 10.1002/j.1552-4604.1989.tb03274.x] - DOI - PubMed
Staquet 1993 {published data only}
    1. Staquet M, Renaud A. Double‐blind, randomized trial of piroxicam and codeine in cancer pain. Current Therapeutic Research 1993;53(4):435‐9.
Strobel 1992 {published data only}
    1. Strobel VE. Drug therapy in severe tumor pain. Comparative study of a new combination preparation versus diclofenac‐Na [Medikamentose Therapie beistarken Tumorschmerzen. Vergleichsstudie eines neuen Kombinationspraparats versus Diclofenac–Na]. Fortschritteder Medizin 1992;110(22):411‐4. - PubMed
Sunshine 1988 {published data only}
    1. Sunshine A, Olson NZ. Analgesic efficacy of ketoprofen in postpartum, general surgery, and chronic cancer pain. Journal of Clinical Pharmacology 1988;28 (12 Suppl):S47–S54. [DOI: 10.1002/j.1552-4604.1988.tb05977.x] - DOI - PubMed
Tonachella 1985 {published data only}
    1. Tonachella R, Curcio C, Grossi E. Diclofenac sodium in cancer pain: A double‐blind within‐patients comparison with pentazocine. Current Therapeutic Research 1985;37(6):1130‐3.
Ventafridda 1975 {published data only}
    1. Ventafridda V, Martino G, Mandelli V, Emanueli A. Indoprofen, a new analgesic and anti‐inflammatory drug in cancer pain. Clinical Pharmacology and Therapeutics 1975;17(3):284‐9. [PUBMED: 47281] - PubMed
Ventafridda 1990b {published data only}
    1. Ventafridda V, Conno F, Panerai AE, Maresca V, Monza GC, Ripamonti C. Non‐steroidal anti‐inflammatory drugs as the first step in cancer pain therapy: double‐blind, within‐patient study comparing nine drugs. Journal of International Medical Research 1990;18(1):21‐9. [PUBMED: 2185963] - PubMed
Weingart 1985 {published data only}
    1. Weingart WA, Sorkness CA, Earhart RH. Analgesia with oral narcotics and added ibuprofen in cancer patients. Clinical Pharmacy 1985;4(1):53‐8. [PUBMED: 3971683] - PubMed
Wool 1991 {published data only}
    1. Wool C, Prandoni P, Polistena P, Ruol A. Ketorolac suppositories in the treatment of neoplastic pain: A randomized clinical trial versus diclofenac. Current Therapeutic Research 1991;49(5):854–61.
Yalcin 1997 {published data only}
    1. Yalín S, Güllü I, Tekuzman G, Savas C. Ketorolac tromethamine in cancer pain. Acta Oncologica 1997;36(2):231‐2. [DOI: 10.3109/02841869709109238] - DOI - PubMed

Additional references

AlBalawi 2013
    1. AlBalawi Z, McAlister FA, Thorlund K, Wong M, Wetterslev J. Random error in cardiovascular meta‐analyses: how common are false positive and false negative results?. Interational Journal of Cardiology 2013;168(2):1102‐7. [DOI: 10.1016/j.ijcard.2012.11.048] - DOI - PubMed
Azevedo São Leão Ferreira 2006
    1. Azevedo São Leão Ferreira K, Kimura M, Jacobsen Teixeira M. The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it?. Supportive Care in Cancer 2006;14(11):1086‐93. [DOI: 10.1016/j.critrevonc.2013.01.001] - DOI - PubMed
Bao 2016
    1. Bao YJ, Hou W, Kong XY, Yang L, Xia J, Hua BJ, et al. Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews 2016, Issue 10. [DOI: 10.1002/14651858.CD011108.pub2] - DOI - PMC - PubMed
Bell 2006
    1. Bell RF, Wisløff T, Eccleston C, Kalso E. Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review. British Journal of Cancer 2006;94(11):1559‐67. [DOI: 10.1038/sj.bjc.6603162] - DOI - PMC - PubMed
Breivik 2009
    1. Breivik H, Cherny N, Collett B, Conno F, Filbet M, Foubert AJ, et al. Cancer‐related pain: a pan‐European survey of prevalence, treatment, and patient attitudes. Annals of Oncology 2009;20(8):1420‐33. [DOI: 10.1093/annonc/mdp001] - DOI - PubMed
Brok 2009
    1. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology 2009;38(1):287‐98. [DOI: 10.1093/ije/dyn188] - DOI - PubMed
Brune 2004
    1. Brune K, Hinz B. The discovery and development of anti‐inflammatory drugs. Arthritis and Rheumatology 2004;50(8):2391‐9. [DOI: 10.1002/art.20424] - DOI - PubMed
Brune 2015
    1. Brune K, Patrignani P. New insights into the use of currently available nonsteroidal anti‐inflammatory drugs. Journal of Pain Research 2015;8:105‐18. [DOI: 10.2147/JPR.S75160] - DOI - PMC - PubMed
Cancer Research UK 2016
    1. Cancer Statistics for the UK. www.cancerresearchuk.org/health‐professional/cancer‐statistics (accessed 7 February 2017).
Carlson 2016
    1. Carlson CL. Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review. Journal of Pain Research 2016;9:515‐34. [10.2147/JPR.S97759. eCollection 2016] - PMC - PubMed
Chell 2005
    1. Chell S, Patsos HA, Qualtrough D, H‐Zadeh AM, Hicks DJ, Kaidi A, et al. Prospects in NSAID‐derived chemoprevention of colorectal cancer. Biochemical Society Transactions 2005;33(Pt 4):667‐71. - PubMed
CNT 2014
    1. Coxib and Traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of nonsteroidal anti‐inflammatory drugs: meta‐analyses of individual participant data from randomised trials. Lancet 2014;382(9894):769‐79. [DOI: 10.1016/S0140-6736(13)60900-9] - DOI - PMC - PubMed
Cooper 2017
    1. Cooper TE, Heathcote LC, Anderson B, Grégoire MC, Ljungman G, Eccleston C. Non‐steroidal anti‐inflammatory drugs (NSAIDs) for cancer‐related pain in children and adolescents. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.CD012563] - DOI - PMC - PubMed
De Conno 1994
    1. Conno F, Caraceni A, Gamba A, Mariani L, Abbattista A, Brunelli C, et al. Pain measurement in cancer patients: a comparison of six methods. Pain 1994;57(2):161‐6. [DOI: 10.1016/0304-3959(94)90219-4] - DOI - PubMed
Deandrea 2008
    1. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Annals of Oncology 2008;19(12):1985‐91. [DOI: 10.1093/annonc/mdn419] - DOI - PMC - PubMed
Dechartes 2013
    1. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ 2013;346:f2304. [DOI: 10.1136/bmj.f2304] - DOI - PMC - PubMed
Dechartres 2014
    1. Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud P. Association between analytic strategy and estimates of treatment outcomes in meta‐analyses. JAMA 2014;312:623‐30. [DOI: 10.1001/jama.2014.8166] - DOI - PubMed
Deng 2012
    1. Deng D, Fu L, Zhao YX, Wu X, Zhang G, Liang C, et al. The relationship between cancer pain and quality of life in patients newly admitted to Wuhan Hospice Center of China. American Journal of Hospital Palliative Care 2012;29(1):53‐9. [DOI: 10.1177/1049909111418636] - DOI - PubMed
Derry 2014
    1. Derry CJ, Derry S, Moore RA. Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD009281.pub3] - DOI - PMC - PubMed
Derry 2017
    1. Derry S, Wiffen PJ, Häuser W, Mücke M, Tölle TR, Bell RF, et al. Oral nonsteroidal anti‐inflammatory drugs for fibromyalgia in adults. Cochrane Database of Systematic Reviews 2017, Issue 3. [DOI: 10.1002/14651858.CD012332.pub2] - DOI - PMC - PubMed
Dreidi 2016
    1. Dreidi MM, Hamdan‐Mansour AM. Pain, sleep disturbance, and quality of life among Palestinian patients diagnosed with cancer. Journal of Cancer Education 2016;31(4):796‐803. [DOI: 10.1007/s13187-015-0946-5] - DOI - PubMed
Dwivedi 2015
    1. Dwivedi AK, Gurjar V, Kumar S, Singh N. Molecular basis for nonspecificity of nonsteroidal anti‐inflammatory drugs (NSAIDs). Drug Discovery Today 2015;20(7):863‐73. [DOI: 10.1016/j.drudis.2015.03.004] - DOI - PubMed
Dworkin 2008
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] - DOI - PubMed
Edwards 2004
    1. Edwards JE, Moore RA, McQuay HJ. Rofecoxib for dysmenorrhoea: meta‐analysis using individual patient data. BMC Womens Health 2004;4(1):3. [DOI: 10.1186/1471-2253-4-3] - DOI - PMC - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
EMEA 2005
    1. European Medicines Agency. EMEA public statement on the suspension of the marketing authorisation for Bextra (valdecoxib) in the European Union. ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500... (accessed 7 February 2017).
EPOC 2015
    1. Effective Practice, Organisation of Care (EPOC). 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 7 February 2017).
Fanelli 2017
    1. Fanelli D, Costas R, Ioannidis JP. Meta‐assessment of bias in science. Proceedings of the National Academy of Sciences of the United States of America 2017;114(14):3714‐9. [DOI: 10.1073/pnas.1618569114] - DOI - PMC - PubMed
FDA 2004
    1. Food, Drug Administration. FDA Public Health Advisory: safety of Vioxx. fda.gov/drugs/drugSafety/postmarketdrugsafetyinformationforpatientsandpr... (accessed 7 February 2017).
Gavaghan 2000
    1. Gavaghan DJ, Moore RA, McQuay HJ. An evaluation of homogeneity tests in meta‐analyses in pain using simulations of individual patient data. Pain 2000;85(3):415‐24. - PubMed
Guyatt 2011
    1. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence ‐ inconsistency. Journal of Cinical Epidemiology 2011;64(12):1294‐302. [DOI: 10.1016/j.jclinepi.2011.03.017] - DOI - PubMed
Guyatt 2013a
    1. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso‐Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66:151‐7. [DOI: 10.1016/j.jclinepi.2012.01.006] - DOI - PubMed
Guyatt 2013b
    1. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables ‐ binary outcomes. Journal of Clinical Epidemiology 2013;66:158‐72. [DOI: 10.1016/j.jclinepi.2012.01.012] - DOI - PubMed
Hadley 2013
    1. Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] - DOI - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hinz 2007
    1. Hinz B, Cheremina O, Bachmakov J, Renner B, Zolk O, Fromm MF, et al. Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. Federation of American Societies for Experimental Biology Journal 2007;21(10):2343‐51. [DOI: 10.1096/fj.06-8061com] - DOI - PubMed
Hinz 2008
    1. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man. Federation of American Societies for Experimental Biology Journal 2008;22(2):383‐90. [DOI: 10.1096/fj.07-8506com] - DOI - PubMed
Häuser 2012
    1. Häuser W, Jung E, Erbslöh‐Möller B, Gesmann M, Kühn‐Becker H, Petermann F, et al. The German fibromyalgia consumer reports ‐ a cross‐sectional survey. BMC Musculoskeletal Disorders 2012;13:74. [DOI: 10.1186/1471-2474-13-74] - DOI - PMC - PubMed
IARC 2012
    1. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed 7 February 2017).
IntHout 2015
    1. IntHout J, Ioannidis JP, Borm GF, Goeman JJ. Small studies are more heterogeneous than large ones: a meta‐meta‐analysis. Journal of Clinical Epidemiology 2015;68:860‐9. [DOI: 10.1016/j.jclinepi.2015.03.017] - DOI - PubMed
Jadad 1995
    1. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 1995;274(23):1870‐3. - PubMed
Laine 2001
    1. Laine L. Approaches to nonsteroidal anti‐inflammatory drug use in the high‐risk patient. Gastroenterology 2001;120(3):594‐606. [DOI: 10.1053/gast.2001.21907] - DOI - PubMed
Mangoni 2010
    1. Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM. Use of nonsteroidal anti‐inflammatory drugs and risk of incident myocardial infarction and heart failure, and all‐cause mortality in the Australian veteran community. British Journal of Clinical Pharmacology 2010;69(6):689‐700. [DOI: 10.1111/j.1365-2125.2010.03627.x] - DOI - PMC - PubMed
McQuay 1998
    1. McQuay H, Moore A. An Evidence‐based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0‐19‐263048‐2]
McQuay 2005
    1. McQuay HJ, Moore RA. Placebo. Postgraduate Medical Journal 2005;81(953):155‐60. [DOI: 10.1136/pgmj.2004.024737] - DOI - PMC - PubMed
McQuay 2007
    1. McQuay HJ, Moore RA. Dose‐response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies. British Journal of Clinical Pharmacology 2007;63(3):271‐8. [DOI: 10.1111/j.1365-2125.2006.02723.x] - DOI - PMC - PubMed
Mercadante 2013
    1. Mercadante S, Giarratano A. The long and winding road of nonsteroidal anti‐inflammatory drugs and paracetamol in cancer pain management: a critical review. Critical Reviews in Oncology/Hematology 2013;87:140‐5. [DOI: 10.1016/j.critrevonc.2013.01.001] - DOI - PubMed
Mikan 2016
    1. Mikan F, Wada M, Yamada M, Takahashi A, Onishi H, Ishida M, et al. The association between pain and quality of life for patients with cancer in an outpatient clinic, an inpatient oncology ward, and inpatient palliative care units. American Journal of Hospital Palliative Care 2016;33(8):782‐90. [DOI: 10.1177/1049909116630266] - DOI - PubMed
Moore 1998
    1. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209‐16. [DOI: 10.1016/S0304-3959(98)00140-7] - DOI - PubMed
Moore 2008
    1. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978–0–931092–69–5]
Moore 2010a
    1. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374‐9. [DOI: 10.1136/ard.2009.107805] - DOI - PMC - PubMed
Moore 2010b
    1. Moore RA, Derry S, McQuay HJ, Straube S, Aldington D, Wiffen P, et al. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain 2010;149(2):173‐6. [DOI: 10.1016/j.pain.2009.08.007] - DOI - PubMed
Moore 2013a
    1. Moore RA, Straube S, Aldington D. Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400‐12. [DOI: 10.1111/anae.12148] - DOI - PubMed
Moore 2013b
    1. Moore RA. What works for whom? Determining the efficacy and harm of treatments for pain. Pain 2013;154 Suppl 1:S77‐86. [DOI: 10.1016/j.pain.2013.03.024] - DOI - PubMed
Moore 2014a
    1. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79‐94. [DOI: 10.1111/papr.12050] - DOI - PubMed
Moore 2014b
    1. Moore RA, Derry S, Simon LS, Emery P. Nonsteroidal anti‐inflammatory drugs, gastroprotection, and benefit‐risk. Pain Practice 2014;14(4):378‐95. [DOI: 10.1111/papr.12100] - DOI - PMC - PubMed
Moore 2015a
    1. Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2015, Issue 9. [DOI: 10.1002/14651858.CD008659.pub3] - DOI - PMC - PubMed
Moore 2015b
    1. Moore RA, Chi CC, Wiffen PJ, Derry S, Rice ASC. Oral nonsteroidal anti‐inflammatory drugs for neuropathic pain. Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD010902.pub2] - DOI - PMC - PubMed
Nabal 2012
    1. Nabal M, Librada S, Redondo MJ, Pigni A, Brunelli C, Caraceni A. The role of paracetamol and nonsteroidal anti‐inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature. Palliative Medicine 2012;26(4):305‐12. [DOI: 10.1177/0269216311428528] - DOI - PubMed
Nguyen 2017
    1. Nguyen TL, Collins GS, Lamy A, Devereaux PJ, Daurès JP, Landais P, et al. Simple randomization did not protect against bias in smaller trials. Journal of Clinical Epidemiology 2017;84:105‐13. [DOI: 10.1016/j.jclinepi.2017.02.010] - DOI - PubMed
NICE 2016
    1. National Institute for Health and Care Excellence. Palliative cancer care ‐ pain. cks.nice.org.uk/palliative‐cancer‐care‐pain (accessed 7 February 2017).
Nüesch 2010
    1. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ 2010;341:c3515. [DOI: 10.1136/bmj.c3515] - DOI - PMC - PubMed
PaPaS 2012
    1. Cochrane Pain, Palliative and Supportive Care Group. PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 7 February 2017).
Portenoy 1999
    1. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999;353(9165):1695‐700. [DOI: 10.1016/S0140-6736(99)01310-0] - DOI - PubMed
Prommer 2015
    1. Prommer EE. Pharmacological management of cancer‐related pain. Cancer Control 2015;22(4):412‐25. [PUBMED: 26678968] - PubMed
Rabbie 2013
    1. Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD008039.pub3] - DOI - PMC - PubMed
RevMan 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Roberts 2015
    1. Roberts I, Ker K, Edwards P, Beecher D, Manno D, Sydenham E. The knowledge system underpinning healthcare is not fit for purpose and must change. BMJ 2015;350:h2463. [DOI: 10.1136/bmj.h2463] - DOI - PubMed
Schmidt‐Hansen 2015a
    1. Schmidt‐Hansen M, Bromham N, Taubert M, Arnold S, Hilgart JS. Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] - DOI - PMC - PubMed
Schmidt‐Hansen 2015b
    1. Schmidt‐Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS. Oxycodone for cancer‐related pain. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5] - DOI - PubMed
Sheen 2002
    1. Sheen CL, Dillon JF, Bateman DN, Simpson KJ, MacDonald TM. Paracetamol pack size restriction: the impact on paracetamol poisoning and the over‐the‐counter supply of paracetamol, aspirin and ibuprofen.. Pharmacoepidemiology and Drug Safety 2002;11(4):329‐31. [DOI: 10.1002/pds.701] - DOI - PubMed
Straube 2014
    1. Straube C, Derry S, Jackson KC, Wiffen PJ, Bell RF, Strassels S, et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD006601.pub4] - DOI - PMC - PubMed
Thorlund 2011
    1. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis ‐ a simulation study. PLOS One 2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491] - DOI - PMC - PubMed
Turner 2013
    1. Turner RM, Bird SM, Higgins JP. The impact of study size on meta‐analyses: examination of underpowered studies in Cochrane reviews. PLOS One 2013;8(3):e59202. [DOI: 10.1371/journal.pone.0059202] - DOI - PMC - PubMed
Twycross 2014
    1. Twycross R, Wilcock A, Howard P. Palliative Care Formulary. PCF5. Nottingham: Palliativedrugs.com Ltd, 2014. [ISBN: 978‐0‐9552547‐9‐6]
Van den Beuken‐van Everdingen 2016
    1. Beuken‐van Everdingen MHJ, Hochstenbach LM, Joosten EA, Tjan‐Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta‐analysis. Journal of Pain and Symptom Management 2016;51:1070‐90. [DOI: 10.1016/j.jpainsymman.2015.12.340] - DOI - PubMed
van Walsem 2015
    1. Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA. Relative benefit‐risk comparing diclofenac to other traditional non‐steroidal anti‐inflammatory drugs and cyclooxygenase‐2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta‐analysis. Arthritis Research and Therapy 2015;17:66. [DOI: 10.1186/s13075-015-0554-0] - DOI - PMC - PubMed
Wender 2015
    1. Wender RC. Aspirin and NSAID chemoprevention, gene‐environment interactions, and risk of colorectal cancer. JAMA 2015;313(11):1111‐2. [DOI: 10.1001/jama.2015.1032] - DOI - PubMed
WHO 2017
    1. Anonymous. WHO analgesic ladder. who.int/cancer/palliative/painladder/en/ (accessed 7 February 2017).
Wiffen 2014
    1. Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD011056.pub2] - DOI - PMC - PubMed
Wiffen 2015
    1. Wiffen PJ, Derry S, Naessens K, Bell RF. Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews 2015, Issue 9. [DOI: 10.1002/14651858.CD011460.pub2] - DOI - PMC - PubMed
Wiffen 2016
    1. Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database of Systematic Reviews 2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] - DOI - PMC - PubMed
Wiffen 2017a
    1. Wiffen PJ, Derry S, Moore RA, McNicol ED, Bell RF, Carr DB, et al. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews 2017, Issue 4. [DOI: 10.1002/14651858.CD012637] - DOI - PMC - PubMed
Wiffen 2017b
    1. Wiffen PJ, Derry S, Moore RA. Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews 2017, Issue 5. [DOI: 10.1002/14651858.CD012508.pub2] - DOI - PMC - PubMed
Wolfe 2014
    1. Wolfe F, Walitt BT, Katz RS, Lee YC, Michaud KD, Häuser W. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. European Journal of Pain 2014;17(4):581‐6. [DOI: 10.1002/j.1532-2149.2012.00234.x] - DOI - PubMed

References to other published versions of this review

Derry 2017a
    1. Derry S, Wiffen PJ, Moore RA, McNicol ED, Bell RF, Carr DB, et al. Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database of Systematic Reviews 2017, Issue 4. [DOI: 10.1002/14651858.CD012638] - DOI - PMC - PubMed
McNicol 2015
    1. McNicol ED, Strassels S, Goudas L, Lau J, Carr DB. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD005180.pub2] - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources